Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii

Felix Yarovinsky, John F. Andersen, Lisa R. King, Patricia Caspar, Julio Aliberti, Hana Golding, Alan Sher

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The protozoan parasite Toxoplasma gondii possesses a protein, cyclophilin-18 (C-18), which binds to the chemokine receptor CCR5, induces interleukin-12 production from murine dendritic cells, and inhibits fusion and infectivity of human immunodeficiency virus 1 (HIV-1) R5 viruses by co-receptor antagonism. Site-directed mutagenesis was employed to identify the domains in C-18 responsible for its CCR5 binding and antiviral functions. To do so we focused on amino acid differences with Plasmodium falciparum cyclophilin, which, although 53% identical with C-18, has minimal binding activity for CCR5, and we generated 22 mutants with substitutions in the regions of non-homology located on the putative surface of the molecule. Two mutations situated on the face of C-18, predicted to be involved in its interaction with the ligand cyclosporin A, were shown to be critical for CCR5-binding and the inhibition of HIV-1 fusion and infectivity. In contrast, four mutations in C-18 specifically designed to abolish the peptidyl-prolyl cis-trans-isomerase activity of the protein failed to inactivate its CCR5 binding and HIV inhibitory activities. Interleukin-12 induction by C-18, on the other hand, was abrogated by mutations effecting either the CCR5 binding or enzymatic function of the molecule. These findings shed light on the structural basis of the molecular mimicry of the chemokine function by a pathogen-derived protein and provide a basis for further modification of C-18 into an antiviral agent.

Original languageEnglish (US)
Pages (from-to)53635-53642
Number of pages8
JournalJournal of Biological Chemistry
Volume279
Issue number51
DOIs
StatePublished - Dec 17 2004

Fingerprint

Toxoplasma
Viruses
Cyclophilins
HIV
Interleukin-12
Mutation
Antiviral Agents
HIV-1
Fusion reactions
Peptidylprolyl Isomerase
Molecular Mimicry
Virus Receptors
Mutagenesis
Proteins
Molecules
Cell Fusion
Chemokine Receptors
Pathogens
Plasmodium falciparum
Site-Directed Mutagenesis

ASJC Scopus subject areas

  • Biochemistry

Cite this

Yarovinsky, F., Andersen, J. F., King, L. R., Caspar, P., Aliberti, J., Golding, H., & Sher, A. (2004). Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii. Journal of Biological Chemistry, 279(51), 53635-53642. https://doi.org/10.1074/jbc.M410550200

Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii. / Yarovinsky, Felix; Andersen, John F.; King, Lisa R.; Caspar, Patricia; Aliberti, Julio; Golding, Hana; Sher, Alan.

In: Journal of Biological Chemistry, Vol. 279, No. 51, 17.12.2004, p. 53635-53642.

Research output: Contribution to journalArticle

Yarovinsky, F, Andersen, JF, King, LR, Caspar, P, Aliberti, J, Golding, H & Sher, A 2004, 'Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii', Journal of Biological Chemistry, vol. 279, no. 51, pp. 53635-53642. https://doi.org/10.1074/jbc.M410550200
Yarovinsky, Felix ; Andersen, John F. ; King, Lisa R. ; Caspar, Patricia ; Aliberti, Julio ; Golding, Hana ; Sher, Alan. / Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii. In: Journal of Biological Chemistry. 2004 ; Vol. 279, No. 51. pp. 53635-53642.
@article{2e9bdfcf4aa34b1d9121a873baf52fb9,
title = "Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii",
abstract = "The protozoan parasite Toxoplasma gondii possesses a protein, cyclophilin-18 (C-18), which binds to the chemokine receptor CCR5, induces interleukin-12 production from murine dendritic cells, and inhibits fusion and infectivity of human immunodeficiency virus 1 (HIV-1) R5 viruses by co-receptor antagonism. Site-directed mutagenesis was employed to identify the domains in C-18 responsible for its CCR5 binding and antiviral functions. To do so we focused on amino acid differences with Plasmodium falciparum cyclophilin, which, although 53{\%} identical with C-18, has minimal binding activity for CCR5, and we generated 22 mutants with substitutions in the regions of non-homology located on the putative surface of the molecule. Two mutations situated on the face of C-18, predicted to be involved in its interaction with the ligand cyclosporin A, were shown to be critical for CCR5-binding and the inhibition of HIV-1 fusion and infectivity. In contrast, four mutations in C-18 specifically designed to abolish the peptidyl-prolyl cis-trans-isomerase activity of the protein failed to inactivate its CCR5 binding and HIV inhibitory activities. Interleukin-12 induction by C-18, on the other hand, was abrogated by mutations effecting either the CCR5 binding or enzymatic function of the molecule. These findings shed light on the structural basis of the molecular mimicry of the chemokine function by a pathogen-derived protein and provide a basis for further modification of C-18 into an antiviral agent.",
author = "Felix Yarovinsky and Andersen, {John F.} and King, {Lisa R.} and Patricia Caspar and Julio Aliberti and Hana Golding and Alan Sher",
year = "2004",
month = "12",
day = "17",
doi = "10.1074/jbc.M410550200",
language = "English (US)",
volume = "279",
pages = "53635--53642",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "51",

}

TY - JOUR

T1 - Structural determinants of the anti-HIV activity of a CCR5 antagonist derived from Toxoplasma gondii

AU - Yarovinsky, Felix

AU - Andersen, John F.

AU - King, Lisa R.

AU - Caspar, Patricia

AU - Aliberti, Julio

AU - Golding, Hana

AU - Sher, Alan

PY - 2004/12/17

Y1 - 2004/12/17

N2 - The protozoan parasite Toxoplasma gondii possesses a protein, cyclophilin-18 (C-18), which binds to the chemokine receptor CCR5, induces interleukin-12 production from murine dendritic cells, and inhibits fusion and infectivity of human immunodeficiency virus 1 (HIV-1) R5 viruses by co-receptor antagonism. Site-directed mutagenesis was employed to identify the domains in C-18 responsible for its CCR5 binding and antiviral functions. To do so we focused on amino acid differences with Plasmodium falciparum cyclophilin, which, although 53% identical with C-18, has minimal binding activity for CCR5, and we generated 22 mutants with substitutions in the regions of non-homology located on the putative surface of the molecule. Two mutations situated on the face of C-18, predicted to be involved in its interaction with the ligand cyclosporin A, were shown to be critical for CCR5-binding and the inhibition of HIV-1 fusion and infectivity. In contrast, four mutations in C-18 specifically designed to abolish the peptidyl-prolyl cis-trans-isomerase activity of the protein failed to inactivate its CCR5 binding and HIV inhibitory activities. Interleukin-12 induction by C-18, on the other hand, was abrogated by mutations effecting either the CCR5 binding or enzymatic function of the molecule. These findings shed light on the structural basis of the molecular mimicry of the chemokine function by a pathogen-derived protein and provide a basis for further modification of C-18 into an antiviral agent.

AB - The protozoan parasite Toxoplasma gondii possesses a protein, cyclophilin-18 (C-18), which binds to the chemokine receptor CCR5, induces interleukin-12 production from murine dendritic cells, and inhibits fusion and infectivity of human immunodeficiency virus 1 (HIV-1) R5 viruses by co-receptor antagonism. Site-directed mutagenesis was employed to identify the domains in C-18 responsible for its CCR5 binding and antiviral functions. To do so we focused on amino acid differences with Plasmodium falciparum cyclophilin, which, although 53% identical with C-18, has minimal binding activity for CCR5, and we generated 22 mutants with substitutions in the regions of non-homology located on the putative surface of the molecule. Two mutations situated on the face of C-18, predicted to be involved in its interaction with the ligand cyclosporin A, were shown to be critical for CCR5-binding and the inhibition of HIV-1 fusion and infectivity. In contrast, four mutations in C-18 specifically designed to abolish the peptidyl-prolyl cis-trans-isomerase activity of the protein failed to inactivate its CCR5 binding and HIV inhibitory activities. Interleukin-12 induction by C-18, on the other hand, was abrogated by mutations effecting either the CCR5 binding or enzymatic function of the molecule. These findings shed light on the structural basis of the molecular mimicry of the chemokine function by a pathogen-derived protein and provide a basis for further modification of C-18 into an antiviral agent.

UR - http://www.scopus.com/inward/record.url?scp=11144234129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144234129&partnerID=8YFLogxK

U2 - 10.1074/jbc.M410550200

DO - 10.1074/jbc.M410550200

M3 - Article

C2 - 15469936

AN - SCOPUS:11144234129

VL - 279

SP - 53635

EP - 53642

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 51

ER -